BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 27525895)

  • 1. Clinical significance of interleukin-4 and interleukin-18 levels in aggressive non-Hodgkin's lymphoma patients.
    Soydinc HO; Guney N; Basaran M; Duranyildiz D; Yasasever V
    Genet Mol Res; 2016 Jul; 15(3):. PubMed ID: 27525895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin's lymphoma.
    Guney N; Soydinc HO; Basaran M; Bavbek S; Derin D; Camlica H; Yasasever V; Topuz E
    Asian Pac J Cancer Prev; 2009; 10(4):669-74. PubMed ID: 19827892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure.
    Stasi R; Zinzani L; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Tura S; Papa G
    Cancer; 1994 Sep; 74(6):1792-800. PubMed ID: 8082082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma.
    Pedersen LM; Klausen TW; Davidsen UH; Johnsen HE
    Ann Hematol; 2005 Aug; 84(8):510-6. PubMed ID: 15834569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of IL-2, IL-6 and IL-10 levels on prognosis in patients with aggressive Non-Hodgkin's Lymphoma (NHL).
    Ozdemir F; Aydin F; Yilmaz M; Kavgaci H; Bektas O; Yavuz MN; Yavuz AA
    J Exp Clin Cancer Res; 2004 Sep; 23(3):485-8. PubMed ID: 15595640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
    Kurzrock R; Redman J; Cabanillas F; Jones D; Rothberg J; Talpaz M
    Cancer Res; 1993 May; 53(9):2118-22. PubMed ID: 8481913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: an exploratory study.
    Kube D; Hua TD; von Bonin F; Schoof N; Zeynalova S; Klöss M; Gocht D; Potthoff B; Tzvetkov M; Brockmöller J; Löffler M; Pfreundschuh M; Trümper L
    Clin Cancer Res; 2008 Jun; 14(12):3777-84. PubMed ID: 18559596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased frequency of circulating Th22 cells in patients with B-cell non-Hodgkin's lymphoma.
    Lu T; Liu Y; Yu S; Yin C; Li P; Ye J; Ma D; Ji C
    Oncotarget; 2016 Aug; 7(35):56574-56583. PubMed ID: 27489357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma.
    Stasi R; Zinzani L; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Venditti A; Del Poeta G; Cantonetti M
    Eur J Haematol; 1995 Jan; 54(1):9-17. PubMed ID: 7859883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Differential diagnostic and prognostic value of serum cytokines (soluble CD30, soluble interleukin-2 receptor, interleukin-10 and interleukin-6) in Hodgkin's disease and lymphosarcomas].
    Iaguzhinskaia OE; Lazarev IE; Nikitin EA; Samoĭlova RS; Loginova IV; Gemdzhan EG; Novikov VA; Mamiliaeva ZKh; Pivnik AV
    Ter Arkh; 2001; 73(4):45-51. PubMed ID: 11494447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of serum IL-2, IL-6 and IL-10 levels with International Prognostic Index in patients with aggressive non-Hodgkin's lymphoma.
    Aydin F; Yilmaz M; Ozdemir F; Kavgaci H; Yavuz MN; Yavuz AA
    Am J Clin Oncol; 2002 Dec; 25(6):570-2. PubMed ID: 12478000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum levels of cytokines and prevalence of autoantibodies in lymphoma patients and their prognostic value.
    Uskudar Teke H; Gulbas Z; Bal C
    J BUON; 2014; 19(1):191-7. PubMed ID: 24659663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum and urine levels of interleukin-8 in patients with non-Hodgkin's lymphoma.
    Lee HL; Eom HS; Yun T; Kim HJ; Park WS; Nam BH; Moon-Woo S; Lee DH; Kong SY
    Cytokine; 2008 Jul; 43(1):71-5. PubMed ID: 18502145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma.
    Legouffe E; Rodriguez C; Picot MC; Richard B; Klein B; Rossi JF; Commes T
    Leuk Lymphoma; 1998 Oct; 31(3-4):351-7. PubMed ID: 9869199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection of soluble interleukin-2 receptor in the serum of patients with non-Hodgkin's lymphoma].
    Pérez Encinas M; Bello JL; Bendaña A; Rabuñal MJ; González S; Abuín I; Noya M; Cadarso C
    Med Clin (Barc); 1998 Jul; 111(5):161-7. PubMed ID: 9732831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma.
    Niitsu N; Okamato M; Nakamine H; Yoshino T; Tamaru J; Nakamura S; Higashihara M; Hirano M
    Eur J Haematol; 2002 Feb; 68(2):91-100. PubMed ID: 12038454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical significance of serum lactate dehydrogenase, β2-microglobulin and vascular endothelial growth factor level detection in patients with non-Hodgkin's lymphoma].
    Duan Y; Li G; Hu HX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):608-10. PubMed ID: 22739165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
    Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
    Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma.
    Stasi R; Zinzani PL; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Papa G; Tura S
    Br J Haematol; 1994 Dec; 88(4):770-7. PubMed ID: 7819101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkin's lymphoma.
    Fischer M; Bijman M; Molin D; Cormont F; Uyttenhove C; van Snick J; Sundström C; Enblad G; Nilsson G
    Leukemia; 2003 Dec; 17(12):2513-6. PubMed ID: 14562126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.